SENS PubMed Publication Search
J Alzheimers Dis. 2020;75(1):45-60. doi: 10.3233/JAD-191081.
doi: 10.3233/JAD-191081.
Yasunari Seita 1, Toshifumi Morimura 2, Naoki Watanabe 2, Chizuru Iwatani 1, Hideaki Tsuchiya 1, Shinichiro Nakamura 1, Toshiharu Suzuki 3, Daijiro Yanagisawa 2, Tomoyuki Tsukiyama 1 4, Masataka Nakaya 1 4, Eiichi Okamura 1, Masanaga Muto 1 4, Masatsugu Ema 1 4, Masaki Nishimura 2, Ikuo Tooyama 2
Abstract:
...Although several groups have developed transgenic mouse models overexpressing the human amyloid-β precursor protein (APP) gene with AD mutations, with and without presenilin mutations, as well as APP gene knock-in mouse models, these animals display amyloid pathology but do not show neurofibrillary tangles or neuronal loss. This presumably is due to differences between the etiology of the aged-related human disease and the mouse models. Here we report the generation of two transgenic cynomolgus monkeys overexpressing the human gene for APP with Swedish, Artic, and Iberian mutations, and demonstrated expression of gene tagged green fluorescent protein marker in the placenta, amnion, hair follicles, and peripheral blood. We believe that these nonhuman primate models will be very useful to study the pathogenesis of dementia and AD. However, generated Tg monkeys still have some limitations. We employed the CAG promoter, which will promote gene expression in a non-tissue specific manner. Moreover, we used transgenic models but not knock-in models. Thus, the inserted transgene destroys endogenous gene(s) and may affect the phenotype(s). Nevertheless, it will be of great interest to determine whether these Tg monkeys will develop tauopathy and neurodegeneration similar to human AD.
PMID: 32250299
Free Full-Text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306892/